Who is sponsoring NCT03589495?

NCT03589495 is sponsored by Ain Shams University.

What drugs are being tested in NCT03589495?

Interventions in NCT03589495: N Acetyl L Cysteine, dextrose 5%.

What condition does NCT03589495 study?

NCT03589495 studies Systemic Inflammatory Response Syndrome.

Is NCT03589495 still recruiting?

NCT03589495 is currently completed. Last updated 18 July 2018.

Last reviewed 2018-07-18 · How we verify

NCT03589495

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Adding Intravenous N-acetyl Cysteine in Colon Surgeries

Completed Phase 4 Last updated 18 July 2018

What this trial tests

Phase 4 trial testing N Acetyl L Cysteine in Systemic Inflammatory Response Syndrome in 60 participants. Completed in 15 October 2016.

Timeline

30 July 2015

Primary endpoint
15 October 2016

15 October 2016

Quick facts

Lead sponsor	Ain Shams University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	60
Start date	30 July 2015
Primary completion	15 October 2016
Estimated completion	15 October 2016

Drugs / interventions tested

N Acetyl L Cysteine — full drug profile →
dextrose 5% — full drug profile →

Conditions studied

Systemic Inflammatory Response Syndrome — all drugs for Systemic Inflammatory Response Syndrome →

Sponsor

Ain Shams University

Who can join

Adults 18 to 80, any sex, with Systemic Inflammatory Response Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The use of antioxidant agents in the prevention or decreasing the severity of postoperative systemic inflammatory response syndrome after colonic surgeries adopted nowadays. Therefore, it is of interest to investigate safety and efficacy of administrating short term intravenous (IV) N acetyl cysteine as add on to l alany l glutamine and total parenteral nutrition on the marker of oxidative stress malondialdehyde and anti- inflammatory marker tumor necrosis factor alpha in patients undergoing colonic surgeries through a prospective, randomized, double blinded, controlled clinical trial

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review).
Zhang X, Wang Z, Zheng Y, Yu Q, et al · · 2023 · cited 84× · PMID 36960868 · DOI 10.3892/ijmm.2023.5238
Safety and efficacy of adding intravenous N-acetylcysteine to parenteral L-alanyl-L-glutamine in hospitalized patients undergoing surgery of the colon: a randomized controlled trial.
Hamamsy ME, Bondok R, Shaheen S, Eladly GH. · · 2019 · cited 9× · PMID 31381364 · DOI 10.5144/0256-4947.2019.251
Enhancing acute inflammatory and sepsis treatment: superiority of membrane receptor blockade.
Mun SJ, Cho E, Kim HK, Gil WJ, et al · · 2024 · cited 2× · PMID 39081318 · DOI 10.3389/fimmu.2024.1424768

Verify or expand the search:

Other trials of N Acetyl L Cysteine

Trials testing the same drug.

NCT07196852 — Redox Status and Exercise Training-induced Adaptations · NA · recruiting
NCT06518044 — NAC for Hematopoietic Recovery in SAA · Phase 2 · not yet recruiting
NCT05126004 — AZA Combined With NAC for PIT After HSCT · Phase 2 · not yet recruiting

Other recruiting trials for Systemic Inflammatory Response Syndrome

Currently open trials in the same condition.

NCT06195267 — Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery ( · NA · recruiting
NCT05969275 — Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock · Phase 2 · recruiting
NCT06052436 — Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With · Phase 1, PHASE2 · recruiting
NCT05663216 — Determinants of Vascular Leakage During Systemic Inflammatory Response Syndrome · recruiting
NCT06028789 — AOrtic Surgery: Systemic Inflammatory Response Versus Sepsis · recruiting

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03589495 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 18 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03589495.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing